Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Eliem Therapeutics (ELYM)
NASDAQ:ELYM
Eliem Therapeutics (ELYM) Stock Price & Analysis
30 Followers
ELYM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.21 - $5.20
Previous Close$3
Volume2.29K
Average Volume (3M)10.89K
Market Cap
$80.98M
Enterprise Value-$27.70M
Total Cash (Recent Filing)$109.37M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)-1.5
Beta-0.16
Next Earnings
Sep 11, 2023EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding26,993,401
10 Day Avg. Volume4,525
30 Day Avg. Volume10,895
Standard Deviation0.22
R-Squared0.02
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.52
Forecast
1Y Price Target
$5.00Price Target Upside66.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Eliem Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELYM FAQ
What was Eliem Therapeutics’s price range in the past 12 months?
Eliem Therapeutics lowest stock price was $2.21 and its highest was $5.20 in the past 12 months.
What is Eliem Therapeutics’s market cap?
Currently, no data Available
When is Eliem Therapeutics’s upcoming earnings report date?
Eliem Therapeutics’s upcoming earnings report date is Sep 11, 2023 which is in 104 days.
How were Eliem Therapeutics’s earnings last quarter?
Eliem Therapeutics released its earnings results on May 11, 2023. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.59.
Is Eliem Therapeutics overvalued?
According to Wall Street analysts Eliem Therapeutics’s price is currently Undervalued.
Does Eliem Therapeutics pay dividends?
Eliem Therapeutics does not currently pay dividends.
What is Eliem Therapeutics’s EPS estimate?
Eliem Therapeutics’s EPS estimate is -$0.25.
How many shares outstanding does Eliem Therapeutics have?
Eliem Therapeutics has 26,993,400 shares outstanding.
What happened to Eliem Therapeutics’s price movement after its last earnings report?
Eliem Therapeutics reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -4.192%.
Which hedge fund is a major shareholder of Eliem Therapeutics?
Among the largest hedge funds holding Eliem Therapeutics’s share is RA Capital Management. It holds Eliem Therapeutics’s shares valued at 38M.
---
Eliem Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (66.67% Upside)
$5.00 (66.67% Upside)
Hedge Fund Trend
Increased
By 121.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.76%
12-Months-Change
Fundamentals
Return on Equity
-39.95%
Trailing 12-Months
Asset Growth
-24.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eliem Therapeutics
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
---
Top 5 ETFs holding ELYM
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold ELYM. The ETFs are listed according to market value of ELYM within the ETF
---
Pieris Pharmaceuticals
―
Frequency Therapeutics
―
SQZ Biotechnologies
―
Armata Pharmaceuticals
―
Galectin Therapeutics
―
---